J P Morgan Chase & Co Analysts Give Merck KGaA (MRK) a €100.00 Price Target
J P Morgan Chase & Co set a €100.00 ($119.05) price objective on Merck KGaA (FRA:MRK) in a research report released on Tuesday morning. The brokerage currently has a neutral rating on the healthcare company’s stock.
A number of other research analysts also recently issued reports on the stock. Oddo Bhf set a €125.00 ($148.81) price target on shares of Merck KGaA and gave the stock a buy rating in a research note on Friday, November 10th. Citigroup set a €123.00 ($146.43) price target on shares of Merck KGaA and gave the stock a buy rating in a research note on Monday, September 25th. Goldman Sachs Group set a €105.00 ($125.00) price target on shares of Merck KGaA and gave the stock a neutral rating in a research note on Tuesday, September 19th. Kepler Capital Markets set a €119.00 ($141.67) price target on shares of Merck KGaA and gave the stock a buy rating in a research note on Thursday, September 21st. Finally, Deutsche Bank set a €99.00 ($117.86) price target on shares of Merck KGaA and gave the stock a neutral rating in a research note on Friday, November 10th. Twelve equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Merck KGaA presently has a consensus rating of Hold and a consensus price target of €107.81 ($128.34).
Merck KGaA (FRA MRK) opened at €90.07 ($107.23) on Tuesday. Merck KGaA has a 12 month low of €87.33 ($103.96) and a 12 month high of €115.00 ($136.90).
ILLEGAL ACTIVITY WARNING: This story was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.watchlistnews.com/j-p-morgan-chase-100-00-price-target/1765554.html.
Merck KGaA Company Profile
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with Analyst Ratings Network's FREE daily email newsletter.